- Design and Implementation Services: ePlus offers comprehensive design and deployment services for AI infrastructure tailored to organization-specific use cases and requirements. The result is a customized plan for implementing infrastructure solutions such as NVIDIA DGX BasePOD that precisely fits the demands of an organization’s AI workloads, for seamless integration with existing systems that can help maximize performance and efficiency.
- Advanced Support Services for AI Infrastructure Solutions: ePlus offers support and maintenance services for NVIDIA DGX BasePOD and other customized AI infrastructure solutions, along with monitoring, updates, and troubleshooting to enable AI infrastructure to perform at optimal levels. As a Certified NVIDIA DGX Ready Managed Services Provider, ePlus brings proven expertise and a commitment to excellence in managing NVIDIA DGX environments.
- Storage-as-a-Service (STaaS) for AI Workloads: To meet the unpredictable storage requirements of AI workloads, ePlus offers an on-premises storage platform that requires no upfront investment, provides consumption-based cost models, and on-demand burst capacity. With financially-backed Service Level Agreements (SLAs) for performance, availability, and energy efficiency, organizations can streamline their data management processes, reduce costs, and enhance their overall AI workflow.
- Data Modernization Services: In preparation for AI initiatives, ePlus offers data modernization services focused on aligning a data strategy with each organization’s specific AI goals, breaking down data silos, and adopting a modern data platform. Aligning business initiatives and data governance helps set up your AI initiatives for success.
AstraZeneca Announced Danicopan As Add-on To Ultomiris Or Soliris Improved Haemoglobin Levels And Maintained Disease Control In Patients With PNH Experiencing Signs Of Clinically Significant Extravascular Haemolysis
Results from ALPHA Phase III trial demonstrated statistically significant increase compared to placebo in mean haemoglobin from baseline to week 12. All key secondary endpoints met statistical superiority, showing
